DrugPatentWatch Database Preview

King Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?

KING PHARMS has twenty-seven approved drugs.

There are six US patents protecting KING PHARMS drugs.

There are seventy-two patent family members on KING PHARMS drugs in thirty-one countries and seven supplementary protection certificates in six countries.

Summary for King Pharms

International Patents:	72
US Patents:	6
Tradenames:	25
Ingredients:	23
NDAs:	27

Drugs and US Patents for King Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-001	May 25, 2001	AB1,AB3	RX	Yes	No	7,067,148		Y
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	AB	RX	Yes	No
King Pharms Llc	PENICILLIN G PROCAINE	penicillin g procaine	INJECTABLE;INJECTION	060101-002	Approved Prior to Jan 1, 1982		RX	No	Yes
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-004	May 25, 2001	AB1,AB3	RX	Yes	No	7,067,148		Y
King Pharms	SYNERCID	dalfopristin; quinupristin	INJECTABLE;INTRAVENOUS	050748-002	Aug 24, 2000		DISCN	No	No
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-002	May 25, 2001	AB1,AB3	RX	Yes	No	6,555,581
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-012	May 25, 2001		DISCN	Yes	No	7,101,569

Expired US Patents for King Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983	3,982,021
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-003	Jan 28, 1991	5,061,722
King Pharms Llc	AVINZA	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021260-006	Dec 18, 2008	6,066,339
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-001	Jan 28, 1991	5,061,722
King Pharms Llc	AVINZA	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021260-005	Dec 18, 2008	6,066,339
King Pharms	PROCANBID	procainamide hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020545-002	Jan 31, 1996	5,656,296
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-003	Jan 28, 1991	4,587,258

Paragraph IV (Patent) Challenges for KING PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	30 mg, 60 mg, 90 mg and 120 mg		2007-06-04
	Tablets	800 mg		2004-11-04
	Extended-release Capsules	45 mg and 75 mg		2009-07-30

International Patents for King Pharms Drugs

Country	Document Number	Estimated Expiration
Austria	303800
China	1368881
Mexico	PA03007338
South Korea	20120055730
Brazil	0013704
European Patent Office	1365745
Israel	148127

Supplementary Protection Certificates for King Pharms Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
13/055	Ireland		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
80030	Netherlands		PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
C/GB98/047	United Kingdom		PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
C0062	France		PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C0001	Belgium		PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
323	Luxembourg		PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• King Pfizer
• King Pharms
• King Pharms Llc